Biology is the most underappreciated destination for capital to flow into over the coming years.
It's the biggest TAM yet to be materially disrupted.
Two plays I like:
The lower risk 2-3x?
$LLY
The higher risk 5-10x?
$ABCL
$LLY first.
Most are still pricing this as a pharma company. That's the mistake.
GLP-1s (Mounjaro/Zepbound) aren't the thesis. They're the nearer term funding engine.
$LLY is building the operating system for human biology.
Think of it just like AWS giving developers infrastructure to build software...Eli Lilly is building the infrastructure to build medicines.
-> Discovers targets
-> Designs molecules
-> Learns from every experiment
Here's what it actually looks like:
-> LillyPod: 1,000 Blackwell GPUs. A wholly owned AI factory for biological discovery.
-> Isomorphic Labs: Frontier AI drug design plugged into their pipeline.
-> TuneLab: BioTech partners train on decades of Lilly's molecular data.
30x PE probably seems pricey right now but if this thesis plays out it's not.
Now
$ABCL:
Earlier stage. More focused. More niche. Potentially huge upside if AI drug discovery works at scale.
Every company sitting on years of proprietary biological data should get re-rated.
$ABCL is arguably the best one out there for that at $1.7B MC.